Vaxcyte, Inc. Financials

Market Capitalization $10.63 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-21.65
Forward PE	-18.11
Price to Sales TTM	$
Price to Book MRQ	$3.11
Enterprise to Revenue
Enterprise to EBITDA	-14.16

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	0.00%
Return on Assets TTM	-14.94%
Return on Equity TTM	-21.06%

Income Statement

Revenue TTM	$0
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$-75,000,000
EBITDA	$-599,025,984
Net Income to Common TTM	$-507,648,000
Diluted EPS TTM	$-4.60
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$2,180,464,896
Total Cash per Share MRQ	$17.50
Total Debt MRQ	$
Total Debt to Equity MRQ	0.82
Current Ratio MRQ	17.88
Book Value per Share MRQ	$27.47

Cash Flow

Operating Cash Flow TTM	$-470,036,000
Levered Free Cash Flow TTM	$-404,953,120

PCVX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	124,637,000
Float Shares	115,468,282
Avg 10 Volume	1,309,980
Avg 30 Volume	None
Shares Short	14,322,764
Short Ratio	13.65
Short % of Shares	13.04%
% Held by Insiders	0.50%
% Held by Institutions	112.07%

Stock Price Summary

Beta	1.01
Fifty Two Week Low	$58.10
Fifty Two Week High	$121.06
Fifty Two Week Change	23.58%
Day 50 MA	$89.65
Day 200 MA	$86.03

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date